Leap Therapeutics (LPTX) has disclosed a new risk, in the Supply Chain category.
Leap Therapeutics’ business risk hinges significantly on NovaRock fulfilling its obligations under the NovaRock Agreement. With NovaRock entrusted to develop, manufacture, and commercialize FL-301 and FL-302 in key Asian markets, Leap Therapeutics’ reliance on NovaRock’s management of the manufacturing process and joint R&D activities is substantial. Leap Therapeutics’ limited influence over NovaRock’s performance poses a critical risk; any failure by NovaRock to meet its development responsibilities could severely impede the progression of FL-301 and FL-302, with potentially detrimental implications for Leap Therapeutics’ business prospects.
Overall, Wall Street has a Strong Buy consensus rating on LPTX stock based on 4 Buys.
To learn more about Leap Therapeutics’ risk factors, click here.
